These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10668457)

  • 21. Therapeutic potential of NMDA receptor antagonists in the treatment of alcohol and substance use disorders.
    Bisaga A; Popik P; Bespalov AY; Danysz W
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2233-48. PubMed ID: 11060803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Role of excitatory amino acids in neuropathology].
    Wikinski SI; Acosta GB
    Medicina (B Aires); 1995; 55(4):355-65. PubMed ID: 8728878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
    Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
    Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB/c mouse strain.
    Long KD; Mastropaolo J; Rosse RB; Manaye KF; Deutsch SI
    Brain Res Bull; 2006 May; 69(6):626-30. PubMed ID: 16716829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pentobarbital-like discriminative stimulus effects of N-methyl-D-aspartate antagonists.
    Willetts J; Balster RL
    J Pharmacol Exp Ther; 1989 May; 249(2):438-43. PubMed ID: 2542531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Medication development issues for opiate addiction.
    Herman BH; Vocci F; Bridge P
    Neuropsychopharmacology; 1995 Dec; 13(4):269-93. PubMed ID: 8747752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-687,414, a low efficacy NMDA receptor glycine site partial agonist in vitro, does not prevent hippocampal LTP in vivo at plasma levels known to be neuroprotective.
    Priestley T; Marshall GR; Hill RG; Kemp JA
    Br J Pharmacol; 1998 Aug; 124(8):1767-73. PubMed ID: 9756395
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postnatal lead exposure and MK-801 sensitivity.
    Cory-Slechta DA
    Neurotoxicology; 1997; 18(1):209-20. PubMed ID: 9216003
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical predictors that the orthosteric mGlu2/3 receptor antagonist LY3020371 will not engender ketamine-associated neurotoxic, motor, cognitive, subjective, or abuse-liability-related effects.
    Witkin JM; Monn JA; Li J; Johnson B; McKinzie DL; Wang XS; Heinz BA; Li R; Ornstein PL; Smith SC; Mitch CH; Calligaro DO; Swanson S; Allen D; Phillips K; Gilmour G
    Pharmacol Biochem Behav; 2017 Apr; 155():43-55. PubMed ID: 28285123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats.
    Zakharova ES; Danysz W; Bespalov AY
    Psychopharmacology (Berl); 2005 Apr; 179(1):128-35. PubMed ID: 15682308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective interaction of nitric oxide synthase inhibition with phencyclidine: behavioural and NMDA receptor binding studies in the rat.
    Klamer D; Zhang J; Engel JA; Svensson L
    Behav Brain Res; 2005 Apr; 159(1):95-103. PubMed ID: 15795002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties.
    Carter C; Benavides J; Legendre P; Vincent JD; Noel F; Thuret F; Lloyd KG; Arbilla S; Zivkovic B; MacKenzie ET
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1222-32. PubMed ID: 2849669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine.
    Witkin JM; Gasior M; Heifets B; Tortella FC
    J Pharmacol Exp Ther; 1999 May; 289(2):703-11. PubMed ID: 10215643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
    Kornhuber J; Weller M; Schoppmeyer K; Riederer P
    J Neural Transm Suppl; 1994; 43():91-104. PubMed ID: 7884411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain.
    Foster AC; Wong EH
    Br J Pharmacol; 1987 Jun; 91(2):403-9. PubMed ID: 2886170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
    Teuns GB; Geys HM; Geuens SM; Stinissen P; Meert TF
    J Pharmacol Toxicol Methods; 2014; 70(3):295-309. PubMed ID: 24632211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.
    Born S; Gauvin DV; Mukherjee S; Briscoe R
    Regul Toxicol Pharmacol; 2017 Jun; 86():181-192. PubMed ID: 28279667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amino acid receptor mediated excitatory synaptic transmission in the cat red nucleus.
    Davies J; Miller AJ; Sheardown MJ
    J Physiol; 1986 Jul; 376():13-29. PubMed ID: 2879036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The NMDA receptor complex: a long and winding road to therapeutics.
    Wood PL
    IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The N-methyl-D-aspartate receptor complex. Various sites of regulation and clinical consequences].
    Turski L
    Arzneimittelforschung; 1990 May; 40(5):511-4. PubMed ID: 1974426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.